13 results on '"Adnot S"'
Search Results
2. Endothelin Dilates Bovine Pulmonary Circulation and Reverses Hypoxic Pulmonary Vasoconstriction
- Author
-
Deleuze, P H, primary, Adnot, S, additional, Shiiya, N, additional, Thoraval, F Roudot, additional, Eddahibi, S, additional, Braquet, P, additional, Chabrier, P E, additional, and Loisance, D Y, additional
- Published
- 1992
- Full Text
- View/download PDF
3. Pulmonary Vascular Reactivity to Endothelin-1 in Normal and Chronically Pulmonary Hypertensive Rats
- Author
-
Eddahibi, S., primary, Raffestin, B., additional, Braquet, P., additional, Chabrier, P. E., additional, and Adnot, S., additional
- Published
- 1991
- Full Text
- View/download PDF
4. New Nitric Oxide Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.
- Author
-
Abid S, Kebe K, Houssaïni A, Tomberli F, Marcos E, Bizard E, Breau M, Parpaleix A, Tissot CM, Maitre B, Lipskaia L, Derumeaux G, Bastia E, Mekontso-Dessap A, and Adnot S
- Subjects
- Anemia, Sickle Cell complications, Anemia, Sickle Cell metabolism, Animals, Antihypertensive Agents metabolism, Cell Proliferation drug effects, Cells, Cultured, Cyclic GMP metabolism, Cyclic Nucleotide Phosphodiesterases, Type 5 metabolism, Disease Models, Animal, Heme Oxygenase-1 metabolism, Hypertension, Pulmonary etiology, Hypertension, Pulmonary metabolism, Hypertension, Pulmonary physiopathology, Hypoxia complications, Male, Membrane Proteins metabolism, Mice, Inbred C57BL, Mice, Transgenic, Muscle, Smooth, Vascular drug effects, Muscle, Smooth, Vascular metabolism, Muscle, Smooth, Vascular pathology, Myocytes, Smooth Muscle drug effects, Myocytes, Smooth Muscle metabolism, Myocytes, Smooth Muscle pathology, Nitric Oxide Donors metabolism, Nitric Oxide Synthase Type III metabolism, Phosphodiesterase 5 Inhibitors pharmacology, Pulmonary Artery metabolism, Pulmonary Artery physiopathology, Anemia, Sickle Cell drug therapy, Antihypertensive Agents pharmacology, Arterial Pressure drug effects, Hypertension, Pulmonary prevention & control, Nitric Oxide metabolism, Nitric Oxide Donors pharmacology, Pulmonary Artery drug effects
- Abstract
Nitric oxide (NO) donors may be useful for treating pulmonary hypertension (PH) complicating sickle cell disease (SCD), as endogenous NO is inactivated by hemoglobin released by intravascular hemolysis. Here, we investigated the effects of the new NO donor NCX1443 on PH in transgenic SAD mice, which exhibit mild SCD without severe hemolytic anemia. In SAD and wild-type (WT) mice, the pulmonary pressure response to acute hypoxia was similar and was abolished by 100 mg/kg NCX1443. The level of PH was also similar in SAD and WT mice exposed to chronic hypoxia (9% O2) alone or with SU5416 and was similarly reduced by daily NCX1443 gavage. Compared with WT mice, SAD mice exhibited higher levels of HO-1, endothelial NO synthase, and PDE5 but similar levels of lung cyclic guanosine monophosphate. Cultured pulmonary artery smooth muscle cells from SAD mice grew faster than those from WT mice and had higher PDE5 protein levels. Combining NCX1443 and a PDE5 inhibitor suppressed the growth rate difference between SAD and WT cells and induced a larger reduction in hypoxic PH severity in SAD than in WT mice. By amplifying endogenous protective mechanisms, NCX1443 in combination with PDE5 inhibition may prove useful for treating PH complicating SCD.
- Published
- 2018
- Full Text
- View/download PDF
5. Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease.
- Author
-
Belhassen L, Carville C, Pelle G, Sediame S, Benacerraf S, Dubois-Randé JL, and Adnot S
- Subjects
- Blood Flow Velocity drug effects, Brachial Artery physiopathology, Coronary Disease physiopathology, Double-Blind Method, Endothelium, Vascular drug effects, Endothelium, Vascular physiopathology, Humans, Male, Middle Aged, Vasodilation drug effects, Brachial Artery drug effects, Coronary Disease drug therapy, Molsidomine therapeutic use, Vasodilator Agents therapeutic use
- Abstract
Flow-mediated vasodilation (FMD) of human blood vessels is essential to adaptation and regulation of peripheral blood flow, and is mediated by endogenously produced nitric oxide. Endothelial function is impaired in many pathologic states, especially in coronary heart disease. We questioned in this study whether exogenous nitric oxide (NO) would restore endothelial dysfunction in peripheral arteries of patients with coronary artery disease (CAD). In a randomized double-blinded case-control assay, we used computerized A-mode ultrasonography to measure diastolic diameters of the brachial artery before and after hyperemia in two groups of 10 patients with CAD. Each group received orally either placebo or 12 mg molsidomine a day for 48 h. In the molsidomine group, FMD was improved with a 60% increase after the first intake of molsidomine, and the same trend was observed after the last intake, although less pronounced. Significant increase in diastolic diameter was observed after the last molsidomine intake, but not after the first one. Thus molsidomine has an early positive effect on FMD in addition to a delayed vasodilator effect. Improvement of endothelial dysfunction by molsidomine in patients with CAD may uncover new therapeutic perceptive in the use of nitrovasodilators.
- Published
- 2000
- Full Text
- View/download PDF
6. Improvement of bradykinin endothelium-mediated vasodilation of forearm resistance circulation by quinaprilat in patients with coronary artery disease with or without left ventricular dysfunction.
- Author
-
Benacerraf S, Carville C, Adnot S, Montagne O, Sediame S, Belhassen L, and Dubois-Randé JL
- Subjects
- Adult, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Aspirin pharmacology, Coronary Angiography, Coronary Disease complications, Dose-Response Relationship, Drug, Drug Interactions, Endothelium, Vascular drug effects, Endothelium, Vascular physiology, Forearm blood supply, Humans, Isoquinolines therapeutic use, Male, Middle Aged, Platelet Aggregation Inhibitors pharmacology, Regional Blood Flow drug effects, Renin blood, Vasomotor System drug effects, Vasomotor System physiology, Ventricular Dysfunction, Left drug therapy, Acetylcholine pharmacology, Angiotensin-Converting Enzyme Inhibitors pharmacology, Bradykinin pharmacology, Coronary Disease drug therapy, Isoquinolines pharmacology, Tetrahydroisoquinolines, Vasodilation drug effects, Ventricular Dysfunction, Left complications
- Abstract
Angiotensin-converting enzyme (ACE) inhibition potentiates bradykinin and acetylcholine endothelium-mediated vasodilation. Three groups were studied. Group I (n = 10) was the reference group; group II was composed of nine patients with coronary artery disease; and group III of seven patients with coronary artery disease and left ventricular dysfunction. Forearm blood flow was measured with plethysmography. Acetylcholine and bradykinin were administered in a random order in the brachial artery at infusion rates of 40 and 80 microg/min and 10, 30, 100 pmol/min, respectively. Then quinaprilat was infused alone at the rate of 50 microg/min and then coinfused with acetylcholine and bradykinin. Five of the reference subjects were pretreated with acetylsalicylate. Acetylcholine and bradykinin increased forearm blood flow in a dose-dependent manner in the three groups. However, the vasodilator responses to both agents were significantly lower in the two groups of patients than in the reference group. Quinaprilat significantly enhanced the vasodilator response to acetylcholine only in subjects of the reference group, whereas it enhanced the vasodilator response to each dose of bradykinin, both in subjects of the reference group and in patients. Pretreatment with aspirin did not change the vasodilator responses in any group. In healthy persons, quinaprilat had no effect on its own on forearm blood flow but enhanced the response to bradykinin and even acetylcholine. In patients with coronary disease, short-term administration of quinaprilat was able to improve the impaired response to bradykinin. The response to acetylcholine, however, could not be significantly enhanced in contrast to that in healthy subjects.
- Published
- 1999
- Full Text
- View/download PDF
7. Local gene delivery within the media of rabbit iliac arteries by using the infiltrator intramural delivery device.
- Author
-
Teiger E, Deprez I, Dupouy P, Sitbon M, Adnot S, and Dubois-Rande JL
- Subjects
- Adenoviridae genetics, Animals, Dextrans, Fluorescent Dyes, Iliac Artery enzymology, Luciferases metabolism, Male, Rabbits, Rhodamines, Angioplasty, Balloon, Coronary instrumentation, Gene Transfer Techniques, Iliac Artery pathology
- Abstract
Percutaneous transluminal angioplasty continues to be limited by restenosis. Prevention of restenosis is now focusing on local delivery of therapeutic agents, such as proliferation-inhibiting genes, directly to the site of arterial injury. We evaluated use of the Infiltrator catheter (IVT, San Diego, CA. U.S.A.) for gene delivery within the arterial media. The goals of our study were to evaluate the histologic effects of the injection and the suitability of the Infiltrator catheter for local delivery of viral therapy. We injected the femoral arteries of 21 New Zealand White rabbits. Six animals were used for an evaluation of the intramural distribution of dextran/rhodamine injected via the Infiltrator catheter. In seven animals, injection site histology and in vitro vasoreactivity were studied after an injection of saline. In the remaining eight animals, a replication-deficient adenovirus encoding for the firefly luciferase gene (Ad RSVLuc) was injected, and luciferase activity was quantified 3 and 8 days later. After injection via the Infiltrator catheter, the fluorescent tracer was distributed throughout the entire circumference and width of the arteries. Histologic examination showed minimal damage with partial endothelial abrasion and disruption of the internal elastic lamina confined to the penetration sites. In vitro endothelium-dependent vasodilation was present at a reduced level after injection via the Infiltrator (maximal endothelium-dependent acetylcholine-induced relaxation, 51.5 +/- 7.4% vs. 23.8 +/- 14.6%; p < 0.05). Significant luciferase expression was found in all the arteries, with a significant increase from day 3 to day 8 (5,392.5 +/- 2,300 vs. 2,012 +/- 471 cpm/mg; p < 0.05). These data obtained in a rabbit iliac artery model show that the Infiltrator catheter is an efficient and safe local intramural delivery device that provides significant transgene expression in the arterial wall without causing significant structural damage.
- Published
- 1999
- Full Text
- View/download PDF
8. Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure.
- Author
-
Carville C, Adnot S, Sediame S, Benacerraf S, Castaigne A, Calvo F, de Cremou P, and Dubois-Randé JL
- Subjects
- Acetylcholine pharmacology, Enzyme Inhibitors pharmacology, Female, Forearm blood supply, Heart Failure blood, Heart Failure classification, Humans, Male, Middle Aged, Nitrates blood, Nitrites blood, Nitroprusside pharmacology, Plethysmography, Severity of Illness Index, omega-N-Methylarginine pharmacology, Heart Failure metabolism, Hemodynamics drug effects, Nitric Oxide metabolism, Vasodilation drug effects, Vasodilator Agents pharmacology
- Abstract
A dissociation between basal and stimulated release of nitric oxide (NO) has been found in the peripheral vasculature of patients with congestive heart failure. To explore basal and stimulated NO-mediated vasodilation in patients with heart failure of varying severity, three groups of subjects were studied: group 1, eight normal subjects; group 2, six patients with moderate heart failure; and group 3, eight patients with severe heart failure. Forearm blood flow (FBF) was measured by plethysmography in response to local brachial infusion of acetylcholine, N(G)-monomethyl-L-arginine (L-NMMA), sodium nitroprusside (SNP), and noradrenaline (NA). The vasodilating response to acetylcholine was markedly impaired in patients with severe heart failure compared with the other groups, with FBF increasing by 59 +/- 19% in group 3 vs. 220 +/- 64% in group 2 (p < 0.05) and 586 +/- 168% in group 1 (p < 0.01) at 80 microg/min acetylcholine. As compared with controls, vasodilation to SNP was impaired in group 3 but unchanged in group 2. NA caused similar vasoconstrictor response in the three groups, whereas vasoconstriction to L-NMMA was less marked in group 3. These results show that vasodilator responses to both acetylcholine and SNP are impaired in patients with heart failure and that this impairment is related to the clinical severity of heart failure.
- Published
- 1998
- Full Text
- View/download PDF
9. Loss of endothelium-dependent relaxation in proximal pulmonary arteries from rats exposed to chronic hypoxia: effects of in vivo and in vitro supplementation with L-arginine.
- Author
-
Carville C, Raffestin B, Eddahibi S, Blouquit Y, and Adnot S
- Subjects
- Acetylcholine pharmacology, Animals, Arginine blood, Calcimycin pharmacology, Endothelins pharmacology, Endothelium, Vascular drug effects, In Vitro Techniques, Male, Molsidomine analogs & derivatives, Molsidomine pharmacology, Muscle Relaxation drug effects, Muscle, Smooth, Vascular physiology, Phenylephrine pharmacology, Pulmonary Artery physiology, Rats, Rats, Wistar, Vasodilation drug effects, Arginine pharmacology, Endothelium, Vascular physiology, Hypoxia physiopathology, Muscle, Smooth, Vascular drug effects, Pulmonary Artery drug effects, Vasodilator Agents pharmacology
- Abstract
To explore endothelium-dependent relaxation and the L-arginine (L-ARG)-nitric oxide (NO) pathway during chronic hypoxia, we examined isolated rings from large conduit pulmonary arteries and aorta from rats exposed to either room air (N), 3-week hypoxia (H), or 3-week H followed by 72-h recovery to normoxia (room air). We examined the vasodilatory actions of acetylcholine (ACh), ionophore A23187, and endothelin-3 (ET-3) on extrapulmonary left and right branches of pulmonary arteries and thoracic aorta precontracted by phenylephrine (PE 10(-6) M). Endothelium-dependent relaxation of N rat pulmonary arteries and aorta to ACh and A23187 was abolished in the presence of L-NG nitroarginine methyl ester (L-NAME 10(-4) M) or methylene blue (MB 10(-5) M) but was suppressed only partially by NG-monomethyl-L-arginine (L-NMMA 5 x 10(-4) M). In pulmonary arteries but not in aorta, ET-3 induced endothelium-dependent relaxation that was suppressed by L-NAME, MB, and L-NMMA. Pulmonary arteries from H rats did not relax with ET-3. As compared with those of N rats, they exhibited less relaxation to ACh and A23187, (47 +/- 3 vs. 89 +/- 2 and 53 +/- 2 vs. 85 +/- 4%, p < 0.001, respectively) but exhibited similar relaxation to the nonendothelium-dependent vasodilator linsidomine. In contrast, endothelial-relaxation did not differ between N and H rat aorta.2+ pretreatment with L-ARG.
- Published
- 1993
- Full Text
- View/download PDF
10. Intracoronary linsidomine abolishes acetylcholine-induced vasoconstriction of epicardial coronary arteries.
- Author
-
Dubois-Rande JL, Dupouy P, Geschwind H, Castaigne A, and Adnot S
- Subjects
- Acetylcholine pharmacology, Coronary Circulation drug effects, Coronary Disease physiopathology, Coronary Vessels physiology, Dose-Response Relationship, Drug, Endothelium, Vascular drug effects, Female, Hemodynamics drug effects, Humans, Male, Middle Aged, Molsidomine administration & dosage, Molsidomine pharmacology, Vasodilation drug effects, Coronary Disease drug therapy, Coronary Vessels drug effects, Molsidomine analogs & derivatives, Vasoconstriction drug effects, Vasodilator Agents pharmacology
- Abstract
If the vasodilation of the epicardial coronary arteries caused by linsidomine (SIN-1), the active metabolite of molsidomine, is well established, few data are available concerning the effects of SIN-1 on the acetylcholine (ACh)-induced vasoconstriction of epicardial coronary arteries. Fourteen patients with mild lesions of the left anterior descending artery (LAD) were studied. Intracoronary blood flow velocity was measured by a Doppler probe placed in the proximal segment of the LAD, and cross-sectional arterial area was assessed by quantitative angiography. After initial hemodynamic parameters were measured, 12 mg papaverine was injected into the left main coronary artery. When hemodynamic parameters returned to baseline values, three increasing concentrations of ACh (5 x 10(-7), 10(-6), and 5 x 10(-6) M) were selectively administered into the LAD in a 3 min period for each concentration. While the infusion of ACh 5 x 10(-6) M was continued, 1 mg SIN-1 was injected as a bolus in the ostium of the left coronary artery. After the injection of papaverine, blood flow increased by 197 +/- 8%, with a trend toward vasoconstriction of the proximal and distal segments of the LAD (p = NS). The ACh injection induced a dose-dependent vasoconstriction, reaching 51 +/- 20% on the distal segment of the LAD at the maximum concentration (p < 0.001). After an initial increase in coronary blood flow of 47 +/- 10 and 28 +/- 11% during the first two concentrations of ACh, respectively, the values decreased after the last injection to the level of baseline values. The infusion of SIN-1 antagonized the ACh-induced vasoconstriction, leading to vasodilation of 7.5 +/- 3% (p < 0.005) and 16 +/- 7% (p < 0.001) of the proximal and distal segments of the LAD, respectively; this was associated with an increase in intracoronary blood flow by 42 +/- 8%. We conclude that intracoronary administration of SIN-1 can antagonize the ACh-induced vasoconstriction of epicardial coronary arteries.
- Published
- 1993
- Full Text
- View/download PDF
11. L-arginine improves endothelium-dependent relaxation of conductance and resistance coronary arteries in coronary artery disease.
- Author
-
Dubois-Randé JL, Zelinsky R, Chabrier PE, Castaigne A, Geschwind H, and Adnot S
- Subjects
- Acetylcholine pharmacology, Coronary Circulation drug effects, Coronary Vessels drug effects, Dose-Response Relationship, Drug, Humans, Hypercholesterolemia physiopathology, Vascular Resistance drug effects, Arginine pharmacology, Coronary Disease physiopathology, Coronary Vessels physiopathology, Endothelium, Vascular physiopathology, Vasodilation drug effects
- Abstract
To assess the ability of L-arginine to improve endothelium-dependent vasodilation in atheromatous coronary arteries, we determined whether intracoronary infusion of L-arginine could improve coronary vascular reactivity to acetylcholine (ACh) examining both conductance and resistance vessels. Coronary blood flow velocity was assessed by positioning a 3 Fr Doppler catheter into the proximal coronary artery segment (six left anterior descending and one circumflex coronary artery). Computed quantitative angiography allowed the measurement of distal diameters. After baseline measurements, ACh was infused at incremental infusion rates through the Doppler lumen catheter (3 min period each) to obtain the estimated concentrations of 5 x 10(-7), 10(-6), and 5 x 10(-6) M. After returning to baseline, L-arginine was infused at the rate of 25 mg/min (10(-3) M) through the Doppler lumen catheter. Infusion of ACh was then repeated according to the same protocol than in the absence of L-arginine. The heart rate and mean arterial blood pressure did not change at any step of the protocol. Infusion of ACh induced dose-dependent vasoconstriction of coronary distal segments with a reduction in coronary distal segments by 39 +/- 15% at 5 x 10(-6) M (p < 0.01). During infusion of L-arginine, the coronary diameter was reduced by only 16 +/- 10% (p < 0.05) at the highest ACh dose. The coronary blood flow velocity increased by 100 +/- 15% at 5 x 10(-7) M ACh (p < 0.05) but only to 16 +/- 15% at 5 x 10(-6) M ACh (NS).(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
12. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy.
- Author
-
Merlet P, Dubois-Randé JL, Adnot S, Bourguignon MH, Benvenuti C, Loisance D, Valette H, Castaigne A, and Syrota A
- Subjects
- 3-Iodobenzylguanidine, Adult, Cardiomyopathy, Dilated diagnostic imaging, Cardiomyopathy, Dilated metabolism, Dobutamine administration & dosage, Dobutamine pharmacology, Female, Heart Failure drug therapy, Heart Failure physiopathology, Hemodynamics physiology, Humans, Infusions, Intravenous, Iodobenzenes metabolism, Male, Middle Aged, Myocardial Contraction drug effects, Norepinephrine blood, Radionuclide Imaging, Cardiomyopathy, Dilated physiopathology, Neurons metabolism, Norepinephrine metabolism, Receptors, Adrenergic, beta drug effects
- Abstract
Desensitization of myocardial beta-adrenergic receptors may result both from an impairment of the norepinephrine (NE) neuronal uptake function and from an increase in circulating NE concentrations. The respective role of these two mechanisms of desensitization was examined in 18 patients with congestive heart failure related to an idiopathic dilated cardiomyopathy. The neuronal NE uptake system was evaluated by [123I]metaiodobenzylguanidine (MIBG) scintigraphy. The desensitization level of beta-adrenoceptors was assessed as the net increase in peak positive left ventricular (LV) dP/dt during intracoronary dobutamine infusion. Arterial NE concentrations were determined at baseline. To obtain control values, we performed MIBG scintigraphy and determined baseline NE concentration in 12 normal subjects. Cardiac MIBG uptake was significantly decreased in patients as compared with controls. This decrease was related to the severity of the disease based on hemodynamic indexes. The inotropic response to intracoronary dobutamine infusion of heart failure patients correlated with both increased baseline NE concentration and diminished cardiac MIBG uptake (r = -0.63, p less than 0.01 and r = 0.73, p less than 0.001, respectively). These findings indicate that the desensitization process is related both to impaired neuronal NE uptake function and increased circulating NE concentrations. Moreover, a subset of 11 patients with moderate heart failure was identified who had diminished cardiac MIBG uptake but normal circulating NE concentrations. This suggests that impairment of the NE uptake function is an early mechanism of desensitization in idiopathic cardiomyopathy. Cardiac MIBG imaging may be a noninvasive means to assess severity of heart failure patients and may also be used to evaluate therapy effects on myocardial alterations of the adrenergic pathway.
- Published
- 1992
- Full Text
- View/download PDF
13. Hemodynamic response to intracoronary infusion of atrial natriuretic factor in patients with normal or altered left ventricular function.
- Author
-
Dubois-Rande JL, Adnot S, Benvenuti C, Merlet P, Hittinger L, Sediame S, Chabrier E, Braquet P, and Castaigne A
- Subjects
- Adult, Aged, Atrial Natriuretic Factor administration & dosage, Atrial Natriuretic Factor blood, Cardiac Catheterization, Cardiac Output drug effects, Coronary Circulation drug effects, Coronary Vessels, Female, Heart Failure physiopathology, Heart Ventricles physiopathology, Humans, Infusions, Intravenous, Male, Middle Aged, Myocardial Contraction drug effects, Vascular Resistance drug effects, Atrial Natriuretic Factor pharmacology, Heart Diseases physiopathology, Hemodynamics drug effects
- Abstract
To assess the effects of atrial natriuretic factor (ANF) on cardiac function, synthetic human ANF was infused directly into the left main coronary artery of eight patients with congestive heart failure (CHF) and six subjects with normal left ventricular (LV) function (controls) who underwent cardiac catheterization. ANF infusion at the incremental rates of 60, 125, 400, and 800 ng/min induced a dose-related increase in plasma ANF concentrations in the coronary sinus, from 1,223 +/- 590 to 3,923 +/- 1,123 pg/ml in patients with CHF (p less than 0.01) and from 1,041 +/- 605 to 2,710 +/- 1,741 pg/ml in controls (p less than 0.01). Peripheral plasma ANF concentrations (femoral artery) increased from 538 +/- 278 to 752 +/- 262 pg/ml (p less than 0.01) in patients with CHF and from 193 +/- 63 to 401 +/- 147 pg/ml (p less than 0.01) in controls. The increase in peripheral or coronary sinus plasma ANF concentrations did not differ between patients with CHF and controls. At the three lowest ANF infusion rates, cardiac index (CI), systemic vascular resistance (SVR), and LV contractility assessed by peak positive dP/dt remained unchanged both in patients with CHF and in controls. At the highest ANF infusion rate, CI increased from 2.18 +/- 0.53 to 2.54 +/- 0.49 L/min/m2 (p less than 0.01) and SVR decreased from 14.6 +/- 3.6 to 12.8 +/- 4.5 mm Hg.min/L (p less than 0.01) in patients with CHF. There was no associated change in heart rate (HR), mean arterial blood pressure (MAP), cardiac filling pressures, or peak positive dP/dt.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.